Literature DB >> 27074934

Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.

Ziva D Cooper1.   

Abstract

Although several chemical structural classes of synthetic cannabinoids (SCs) were recently classified as Schedule I substances, rates of use and cases of serious toxic effects remain high. While case reports and media bring attention to severe SC toxicity, daily SC use resulting in dependence and withdrawal is a significant concern that is often overlooked when discussing the risks of these drugs. There is a rich literature on evidence-based approaches to treating substance use disorders associated with most abused drugs, yet little has been published regarding how to best treat symptoms related to SC dependence given its recency as an emerging clinically significant issue. This review provides a background of the pharmacology of SCs, recent findings of adverse effects associated with both acute intoxication and withdrawal as a consequence of daily use, and treatment approaches that have been implemented to address these issues, with an emphasis on pharmacotherapies for managing detoxification. In order to determine prevalence of use in cannabis smokers, a population at high risk for SC use, we obtained data on demographics of SC users, frequency of use, and adverse effects over a 3.5-year period (2012-2015) in the New York City metropolitan area, a region with a recent history of high SC use. While controlled studies on the physiological and behavioral effects of SCs are lacking, it is clear that risks associated with using these drugs pertain not only to the unpredictable and severe nature of acute intoxication but also to the effects of long-term, chronic use. Recent reports in the literature parallel findings from our survey, indicating that there is a subset of people who use SCs daily. Although withdrawal has not been systematically characterized and effective treatments have yet to be elucidated, some symptom relief has been reported with benzodiazepines and the atypical antipsychotic, quetiapine. Given the continued use and abuse of SCs, empirical studies characterizing (1) SCs acute effects, (2) withdrawal upon cessation of use, and (3) effective treatment strategies for SC use disorder are urgently needed.

Entities:  

Keywords:  Adverse effects; Cannabis; Dependence; K2; Spice; Synthetic cannabinoid; Withdrawal

Mesh:

Substances:

Year:  2016        PMID: 27074934      PMCID: PMC4923337          DOI: 10.1007/s11920-016-0694-1

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  56 in total

1.  Myocardial infarction associated with use of the synthetic cannabinoid K2.

Authors:  Arshid Mir; Adebisi Obafemi; Amy Young; Colin Kane
Journal:  Pediatrics       Date:  2011-11-07       Impact factor: 7.124

2.  Novel psychoactive drug use among younger adults involved in US nightlife scenes.

Authors:  Brian C Kelly; Brooke E Wells; Mark Pawson; Amy Leclair; Jeffrey T Parsons; Sarit A Golub
Journal:  Drug Alcohol Rev       Date:  2013-06-24

3.  Synthetic cannabinoid-induced psychosis: two adolescent cases.

Authors:  Olumide O Oluwabusi; Liudmila Lobach; Umair Akhtar; Branden Youngman; Paul J Ambrosini
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-10       Impact factor: 2.576

4.  Relative reinforcing strength of three N-methyl-D-aspartate antagonists with different onsets of action.

Authors:  G Winger; S R Hursh; K L Casey; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  2002-05       Impact factor: 4.030

Review 5.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

6.  College students and use of K2: an emerging drug of abuse in young persons.

Authors:  Xingdi Hu; Brian A Primack; Tracey E Barnett; Robert L Cook
Journal:  Subst Abuse Treat Prev Policy       Date:  2011-07-11

7.  Beyond THC: The New Generation of Cannabinoid Designer Drugs.

Authors:  Liana Fattore; Walter Fratta
Journal:  Front Behav Neurosci       Date:  2011-09-21       Impact factor: 3.558

8.  Synthetic cannabis-induced mania.

Authors:  Mehmet Fatih Ustundag; Esra Ozhan Ibis; Atakan Yucel; Halil Ozcan
Journal:  Case Rep Psychiatry       Date:  2015-03-09

9.  Notes from the Field: Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use - United States, January-May 2015.

Authors:  Royal Law; Josh Schier; Colleen Martin; Arthur Chang; Amy Wolkin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-12       Impact factor: 17.586

10.  Withdrawal phenomena and dependence syndrome after the consumption of "spice gold".

Authors:  Ulrich S Zimmermann; Patricia R Winkelmann; Max Pilhatsch; Josef A Nees; Rainer Spanagel; Katja Schulz
Journal:  Dtsch Arztebl Int       Date:  2009-07-03       Impact factor: 5.594

View more
  41 in total

1.  In vitro determination of the efficacy of illicit synthetic cannabinoids at CB1 receptors.

Authors:  Shivani Sachdev; Kiran Vemuri; Samuel D Banister; Mitchell Longworth; Michael Kassiou; Marina Santiago; Alexandros Makriyannis; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-12-10       Impact factor: 8.739

Review 2.  Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.

Authors:  Eun Yong Chung; Hye Jin Cha; Hyun Kyu Min; Jaesuk Yun
Journal:  Arch Pharm Res       Date:  2021-04-02       Impact factor: 4.946

Review 3.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

4.  Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073.

Authors:  Ziva D Cooper; Justin L Poklis; Fei Liu
Journal:  Neuropharmacology       Date:  2017-11-14       Impact factor: 5.250

5.  Synthetic cannabinoids found in "spice" products alter body temperature and cardiovascular parameters in conscious male rats.

Authors:  Charles W Schindler; Benjamin R Gramling; Zuzana Justinova; Eric B Thorndike; Michael H Baumann
Journal:  Drug Alcohol Depend       Date:  2017-08-18       Impact factor: 4.492

Review 6.  Role of cannabis in cardiovascular disorders.

Authors:  Hemant Goyal; Hamza H Awad; Jalal K Ghali
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 7.  New psychoactive substances: Pharmacology influencing UK practice, policy and the law.

Authors:  David Nutt
Journal:  Br J Clin Pharmacol       Date:  2020-02-04       Impact factor: 4.335

8.  In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201).

Authors:  Xingxing Diao; Jeremy Carlier; Mingshe Zhu; Shaokun Pang; Robert Kronstrand; Karl B Scheidweiler; Marilyn A Huestis
Journal:  Forensic Toxicol       Date:  2016-07-06       Impact factor: 4.096

9.  Age, period, and cohort effects in synthetic cannabinoid use among US adolescents, 2011-2015.

Authors:  Katherine M Keyes; Caroline Rutherford; Ava Hamilton; Joseph J Palamar
Journal:  Drug Alcohol Depend       Date:  2016-07-28       Impact factor: 4.492

Review 10.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.